The firm will also receive potential royalty payments on net sales of investigational voretigene neparvovec outside the US.
Spark Therapeutics chief business officer Dan Faga said: “By leveraging Novartis’ large, existing commercial and medical infrastructure in ophthalmology, as well as its commitment to commercialising genetic-based medicines, we help ensure that more patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy who live outside the US, and importantly outside of Europe, have access to investigational voretigene neparvovec.
“We intend to use the proceeds from this transaction to continue to develop our robust pipeline of investigational gene therapies to create a path to a world where no life is limited by genetic disease.”
The firm additionally signed a separate agreement for the manufacture and supply of investigational voretigene neparvovec to Novartis.
Leave a Reply